Abstract：
Breast implant insertion for breast reconstruction or breast augmentation is a developing procedure, with high demand worldwide-being the second most common plastic surgery in the US as of 2022. Breast-implant-associated anaplastic large cell lymphoma (BIA-ALCL) is T-cell, non-Hodgkin lymphoma, typically CD30+, ALK-, presenting with fluid collection in the inner aspect of the peri-implant capsule in most patients, with the onset exceeding 1-year after implantation. The mean time between breast implant insertion and BIA-ALCL development is 7-10 years. The main risk factor is the use of textured implants because of their susceptibility to triggering local inflammation and immune stimulation finally leading to lymphoproliferation. Genetic predispositions to hereditary breast cancer increase the risk of disease development as well. BIA-ALCL seems to be underestimated in many countries and the initial symptom-seroma might be overlooked and misdiagnosed. Despite its rarity, the awareness of the disease should be improved among patients and medical professionals. This paper summarizes epidemiology, etiopathogenesis, differential diagnosis, and treatment-both surgical and hematological approaches.
摘要：
乳房植入物插入乳房重建或隆胸是一个发展中的程序，在全球范围内具有很高的需求-截至2022年，它是美国第二大最常见的整形手术。乳房植入物相关的间变性大细胞淋巴瘤（BIA-ALCL）是T细胞，非霍奇金淋巴瘤,通常是CD30+，ALK-,在大多数患者中，在植入物周围囊的内部方面表现出液体收集，发病超过植入后1年。乳房植入物插入和BIA-ALCL发展之间的平均时间为7-10年。主要风险因素是使用纹理植入物，因为它们容易引发局部炎症和免疫刺激，最终导致淋巴增生。遗传性乳腺癌的遗传易感性也会增加疾病发展的风险。在许多国家，BIA-ALCL似乎被低估了，最初的症状-血清肿可能会被忽视和误诊。尽管它很罕见,应提高患者和医务人员对这种疾病的认识。本文总结了流行病学，病因，鉴别诊断,和治疗-手术和血液学方法。
